drug
sugammadex sodium
Marketedupdated 3mo agoby B. Braun Medical Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying sugammadex sodium
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 12, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Jul 27, 2026patentUS RE44733*PED
- Jul 27, 2026patentUS RE44733*PED
- Jan 27, 2026compositionUS RE44733
- Jan 27, 2026compositionUS RE44733
FDA exclusivities (4)
- Jun 12, 2028PEDPediatric (6mo bonus)1.8y
- Jun 12, 2028PEDPediatric (6mo bonus)1.8y
- Dec 12, 2027NPPNew Product (3y)1.3y
- Dec 12, 2027NPPNew Product (3y)1.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that